 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox won an administrative suit seeking the KFDA's order to suspend manufacturing and sales of three botulinum toxin "Medytoxin" products and cancel the item license.
Global pharmaceutical bio company Medytox said on the 9th that the third administration of the Daejeon District Court has ruled the cancellation of all dispositions in a lawsuit to cancel the disposal of three medi toxin items (50, 100, 150 units) filed against the head of the Daejeon Regional Food and Drug Administration.
The Ministry of Food and Drug Safety ordered the cancellation of item licenses for the three products in 2020 in violation of the Pharmaceutical Affairs Act, saying it manipulated documents as if Medytox used an unauthorized solution and produced it as a licensed solution in the process of producing medi toxin from 2012 to 2015.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
